ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
A Network Pharmacology-Based Investigation into the Mechanism of Quercetin Combined with Rosuvastatin in Delaying Diabetic Nephropathy via Inhibiting NRK-52E Cell Ferroptosis.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oxidative Stress in Diabetic Cardiomyopathy: Molecular Mechanisms, Current Treatment and Therapeutic Potential of Plant Antioxidants.Antioxidants (Basel, Switzerland) · 2026Review
- Iron-Driven Ferroptosis in Diabetic Kidney Disease: From Molecular Mechanisms to Targeted Therapeutic Translation.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Diabetic nephropathy (DN) is a leading cause of end-stage renal disease, and current therapeutic options are limited in effectively managing DN progression. Renal tubular epithelial cell (RTEC) ferroptosis has emerged as a critical mechanism contributing to DN pathogenesis. This study aimed to investigate the potential synergistic effects of quercetin (QCT) and rosuvastatin (RSV) on inhibiting RTEC ferroptosis and ameliorating DN progression, providing a novel combinatorial therapeutic strategy. Methods: Public database data were analyzed using network pharmacology to identify QCT-DN-related and RSV-DN-related targets, followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. NRK-52E cells were cultured in vitro under high glucose conditions (30 mM glucose) to induce damage, then incubated with QCT and/or RSV. Enzyme-linked immunosorbent assay measured inflammatory cytokines (IL-6, TGF-β, TNF-α), flow cytometry detected reactive oxygen species (ROS), and colorimetric assays quantified superoxide dismutase (SOD), malondialdehyde (MDA), and iron ions. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) evaluated ferroptosis-related genes (GPX4, SLC7A11). Results: Network pharmacology analysis revealed primary enrichment of both QCT-DN-related and RSV-DN-related targets in ferroptosis-related pathways. In vitro cell experiments showed that both QCT and RSV, when used individually, significantly inhibited the expression of inflammatory cytokines (IL-6, TGF-β, and TNF-α), ROS generation, SOD levels, MDA levels, iron ion levels, and the expression of ferroptosis-related genes (GPX4 and SLC7A11) in NRK-52E cells under high-glucose conditions. Furthermore, compared to the individual use of QCT or RSV, the combined use of QCT and RSV demonstrated a more significant inhibitory effect on the inflammatory phenotype and ferroptosis levels in NRK-52E cells. Conclusion: This study highlights the potential of combining QCT and RSV for DN management. Network pharmacology confirmed associations between QCT/RSV targets and NRK-52E cell ferroptosis. In vitro experiments validated superior protective effects of co-treatment over individual treatments, warranting further in vivo investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.